Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372496
Licensor grants an exclusive, worldwide license to make, use, sell, offer for sale and import NRobeâ„¢ Film, NRobeâ„¢ Equipment and NRobeâ„¢ Process under the Licensed Patent Applications (B) in the field of the NRobeâ„¢ System in the Territory including improvements thereto.
Licensor grants an exclusive, worldwide license to use the Technical Information in the field of the NRobeâ„¢ system.
The Licensed Patents Applications (A) are titled
Powder Compaction and Enrobing; and, Improvements in Powder Compaction and Enrobing.
The Licensed Patents Applications (B) are titled
Improvements in or Relating to Encapsulation;
Capsule Based Drug Delivery System;
Improvements in/ or Relating to Modified Cellulose Films;
Modified Polymeric Films;
Oxygen Scavenger in Films;
Improvements in Glues; and,
Improvements in Glues and their Applications.
NRobe is a solid oral dose system capable of enrobing a variety of powders and particulates within dry polymer films to produce an elegant dose form comparable in appearance to film-coated or gel-dipped tablets, or two-piece hard capsules. This system can deliver benefits such as unique appearance, improved drug release, simplified formulation and processing, and the avoidance of problematic excipients.
IPSCIO Record ID: 274906
During the term, Licensor agrees not to manufacture a prescription prenatal vitamin product for sale or distribution within the United States which uses any of the following PantoneÂ® colors 247C, 248C, 249C, 253C, 254C and 255C, or has enrobing containing the two colors to be mutually agreed upon in writing by the Parties.
With this amendment, Products shall be gelatin enrobed using the patented SofletÂ® technology and patents.
IPSCIO Record ID: 211880
– a non-exclusive license to use the Licensed Technology to use, adapt and modify and enhance the Prototype Machine to develop and produce Tabwrap Machines in the Territory for the duration of this Agreement;
– an exclusive license to use the Licensed Technology to manufacture, have manufactured, use or sell the Products in the Exclusive Field in the Territory for the duration of this Agreement;
– a non-exclusive license to use the Licensed Technology to manufacture, have manufactured, use or sell the Products in the Non-exclusive Field in the Territory for the duration of this Agreement;
– a non-exclusive license to use the Licensed Technology and/or the Xgel Tabwrap Film Technology to manufacture, have manufactured, use or sell the XGel Tabwrap Film in the Territory for the duration of this Agreement.
The product means any Tablet which is manufactured using the Licensed Technology or any Improvements.
The patent applications are for a drug delivery system and encapsulation.
The know-how means all confidential information, including that comprised in formulae, techniques, designs, specifications, drawings, components lists, manuals, instructions and catalogues, whether in human or machine readable form that does not comprise Patents and relating to the XGel System, the Tabwrap Technology, the Prototype Machine and the XGel Tabwrap Film Technology; the Products and/or the composition or production of the Products using the Prototype Machine and/or the XGel System and/or the Tabwrap Technology; the design, development, manufacture or use of the Products using the Prototype Machine and/or the XGel System and/or the Tabwrap Technology; and the repair and maintenance of the Products and the Prototype Machine.
The TABWRAPâ„¢ process is revolutionary and incorporates state of the art technology in fast tablet processing, innovative film cutting and a unique overlap film tamper-evident sealing process. The ability to manipulate the dissolution rates of the tablet wrapping film formulations enables BioProgress to design-in advanced rapid active release characteristics.
The non-exclusive field means the market for orally ingestible pharmaceutical and nutritional Products for humans (but not animals) outside the Exclusive Field.
IPSCIO Record ID: 248396
Licensor grants to Licensee and its permitted sublicensees and Affiliates a non-exclusive license to the Licensor Trademarks identified during the term of this Agreement for the purpose of performing its obligations under this Agreement. The Trademarks are to be used in labeling of Licensed Product as requested as well as use name and derivations thereof in promoting, marketing and selling of Licensed Product in the Territory.
Oral Disintegrating Tablets shall mean a solid tablet dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds when taken orally.
Trademarks shall mean the trademarks, tradenames (and registrations and applications therefor) controlled by each of the parties and used on Licensed Product, (Oral Disintegrating Tablets) including, initially the applicable Licensor Trademarks listed hereto and the applicable Ascent Trademarks listed hereto.
CIMA LABS INC.
Licensor Technical Information shall mean (a) techniques and data, including ideas, inventions (including patentable inventions, but excluding inventions covered by Licensor Licensed Patents), practices methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing, patent data or descriptions relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates and (b) chemical formulations, compositions of matter, product samples and assays relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates. Licensor Technical Information shall include Developed Intellectual Property. Licensor Technical Information shall not include any Work Product.
Licensor Licensed Patents shall mean the patents and patent applications owned or Controlled by Licensor and/or its Affiliates that claim Licensed Product, the DuraSolv(R) Technology, the PakSolv(R) Technology and/or the OraSolv(R) Technology as related to Licensed Product, and its manufacture, its packaging, or its use, its import or its sale and including any extension, reissue, renewal, reexamination or continuation-in-part of such patents or patent applications. Licensor Licensed Patents shall include Developed Intellectual Property. Licensor Licensed Patents shall not include any Work Product. The initial list of Licensor Licensed Patents is set forth.
U.S. Pat. No. 5,178,878 – Effervescent dosage form with microparticles
U.S. Pat. No. 6,155,423 – Blister package and packaged tablet
U.S. Pat. No. 6,024,981 – Rapidly dissolving robust dosage form
U.S. Pat. No. 6,221,392 – Rapidly dissolving robust dosage form
DuraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patents 6,024,981 and 6,221,392 and PCT Published Application No. WO 98/46215.
PakSolv(R)Technology shall mean the packaging system generally described in U.S. Patents 6,155,423; 6,269,615 and 6,311,462.
OraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patent 5,178,878 and U.S. Patent Application 08/468,913.